Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.352 FI de cinco anos: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v20.i1.20
40 pages

CD4+ T Cells in Adoptive Immunotherapy and the Indirect Mechanism of Tumor Rejection

Peter A. Cohen
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Liaomin Peng
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Gregory E. Plautz
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Julian A. Kim
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
David E. Weng
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Suyu Shu
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

RESUMO

Tumor-specific CD4+ effector T cells often play a decisive role in immunologic tumor rejection, in some cases without evident co-participation of CD8+ T cells. During such CD4+ T-cell-mediated rejection there is often no delectable direct contact between T cells and tumor cells. Optimally prepared, adoptively transferred CD4+ T cells can reject established tumors with great efficiency even when targeted tumor cells express no MHC Class II molecules, implying that recognition of tumor antigen (Ag) occurs via MHC Class II-expressing host antigen-presenting cells (APC) within the tumor. Because consequent rejection also excludes Ag-specific contact between CD4+ T cells and MHC Class IIneg tumor cells, the most critical CD4+ T-cell-mediated event is likely cytokine release, resulting in an accumulation and activation of accessory cells such as tumoricidal macrophages and lymphokine-activated killer cells. Although such an indirect rejection mechanism may appear antithetical to popular strategies centered on CD8+ cytotoxic T cells (CTL), current evidence suggests that even CD8+ T-cell-mediated recognition/rejection often bypasses direct tumor cell contact and is largely cytokine mediated. While CTL are likely to participate prominently in many models of tumor rejection, indirect mechanisms of recognition/ rejection have the theoretical advantage of remaining operative even when individual tumor cells evade direct contact by down-regulating MHC and/or Ag expression


Articles with similar content:

Cross-Presentation of Antigens by Dendritic Cells
Critical Reviews™ in Immunology, Vol.22, 2002, issue 5-6
William R. Heath, Francis R. Carbone, Gabrielle T. Belz
T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Brian J. Czerniecki, Jorgen Kjaergaard, Liaomin Peng, Peter A. Cohen, Gary K. Koski, James H. Finke, Suyu Shu, Gregory E. Plautz
CD40 and Dendritic Cell Function
Critical Reviews™ in Immunology, Vol.23, 2003, issue 1-2
Ranjeny Thomas, Brendan O'Sullivan
Mechanisms of Induction of Tolerance to Organ Allografts
Critical Reviews™ in Immunology, Vol.20, 2000, issue 4
Bruce Hall
Tumor Antigen Presentation by Dendritic Cells
Critical Reviews™ in Immunology, Vol.30, 2010, issue 4
Nina Dickgreber, Ian F. Hermans, Troels R. Petersen